Loading...

Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leuk Lymphoma
Main Authors: DiMaggio, Elizabeth, Zhou, Jun-Min, Caddell, Ryan, Tombleson, Rebecca, Perkins, Janelle, Anasetti, Claudio, Khimani, Farhad, Pidala, Joseph, Nishihori, Taiga, Perez, Lia, Betts, Brian, Fernandez, Hugo F., Mishra, Asmita
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771324/
https://ncbi.nlm.nih.gov/pubmed/32133897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1731498
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!